Funding received for Phase 2a/b Clinical Trials

MindBio announces $1.44 million government grant funding for Phase 2a/b Clinical Trials Microdosing LSD in Major Depressive Disorder.

We are pleased to announce that MindBio’s research collaborators at the University of Auckland in New Zealand have received $1.44 milion in government grant funding to advance Phase 2a/b clinical trials Microdosing LSD in Major Depressive Disorder.

Vancouver, British Columbia – TheNewswire - July 25, 2022 – Blackhawk Growth Corp. (CSE:BLR); (Frankfurt:0JJ); (OTC:BLRZF) (the “Company” or “Blackhawk”) subsidiary, MindBio Therapeutics’ (“MindBio”) research collaborators at the University of Auckland in New Zealand have received NZ$1.44 million in funding from the Health Research Council of New Zealand  to conduct a trial of LSD (Lysergic Acid Diethylamide) microdosing in patients with Major Depressive Disorder.

The grant funding comes after the recent successful completion of a Phase 1 Clinical Trial in 80 healthy participants.  The data from this Phase 1 trial is currently being collated and MindBio will make further announcements as information comes to hand.

MindBio is working exclusively in psychedelic microdosing clinical trials with scientific collaborators at the University of Auckland to develop intellectual property and novel microdosing treatments for mental health conditions that can be commercialized and used to treat patients in the primary health care system.

“We are proud of the work of our scientific collaborators and the substantial support shown is testament to the calibre of scientists leading the project.   We are determined to develop game-changing treatments for mental health conditions” said Frederick Pels, CEO of Blackhawk Growth Corp.

Read the full announcement here.